Tvardi Therapeutics to host KOL webinar on TTI-109 potential in ulcerative colitis
TVRD•Webinar details
Tvardi Therapeutics will host a KOL webinar on Aug. 19, 2026 at 11:00 a.m. ET focused on TTI-109 in ulcerative colitis.
Topics to be covered
The session will feature new company data, a review of Phase 1 healthy-volunteer results, and a discussion of planned clinical development strategy.
External medical perspective
Randy Longman, MD, PhD of Weill Cornell Medicine will join management to discuss the UC treatment landscape and unmet needs.
